secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001104659-23-088596
Event type: litigation
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 1.02, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax to pay $149.75M to SK bioscience, sells $84.5M in stock to settle dispute
--------------------------------------------------------------------------------

- Settlement payment of $149.75M for canceled manufacturing statements of work; $130.4M due Aug 10, 2023.
- Novavax issues 6.5M shares at $13.00 per share to SK for $84.5M gross proceeds, closing expected Aug 10.
- SK gets exclusive South Korea license for COVID vaccine tech through Feb 2029; non-exclusive for Thailand/Vietnam through June 2028.
- Net cash outflow of ~$65.25M after settlement payment and stock proceeds; $19.35M balance due Nov 15, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465923088596/0001104659-23-088596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465923088596/tm2323012d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer